BioTime Commences Shipment of Stem Cell Research Pr
January 05, 2010 04:40 PM Eastern Time
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE Amex:BTIM) announced today that it has initiated shi
cell research products to its worldwide distributor, Millipore Corporation, according to the terms of the co-marketing agreement be
companies that was announced on July 9, 2009. BioTime has shipped inventory of six ACTCellerate™ progenitor cell lines to Milli
begin shipments of additional cell lines and ESpan™ cell growth media in the next several weeks. Derived from human embryonic st
fully differentiated into specific cell types, each ACTCellerate™ line provides a convenient, highly purified source of progenitor cells
applications in drug discovery, research, and the development of therapeutic products.
BioTime's research products will soon be available to be ordered by researchers through Millipore's stem cell homepage,
www.millipore.com/stemcells. Millipore, which is already a leading supplier of stem cell research reagents, plans a full launch for Bio
cell lines and growth media during the first quarter of 2010.
BioTime’s progenitor cell lines and growth media are also being offered through BioTime Asia, Limited as research products to pre
based stem cell research centers in the People’s Republic of China.
“Many researchers prefer to work with well-characterized progenitor cells rather than starting from scratch with embryonic stem cel
D. West, Ph.D., CEO of BioTime. “The ACTCellerate™ product line allows scientists to save time and money, and to accomplish
research goals. We look forward to working with Millipore’s outstanding marketing team to make these cell lines widely available t
worldwide, allowing them to more quickly perform the research and development work that may lead to life-saving therapies.”
“We are pleased to be entering a new stage in the development of BioTime’s business as we begin to generate revenues not only fr
FDA-approved blood plasma volume e